Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PMD

Psychemedics (PMD) Stock Price, News & Analysis

Psychemedics logo

About Psychemedics Stock (NASDAQ:PMD)

Advanced Chart

Key Stats

Today's Range
$2.46
$2.77
50-Day Range
$2.32
$3.21
52-Week Range
$1.63
$3.25
Volume
113,627 shs
Average Volume
26,272 shs
Market Capitalization
$16.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol. The company's testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. It offers its services to employers for job applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. The company was incorporated in 1986 and is headquartered in Dallas, Texas.

Receive PMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Psychemedics and its competitors with MarketBeat's FREE daily newsletter.

PMD Stock News Headlines

Psychemedics announces reverse stock split, forward stock split
From Social Security to Social Prosperity?
In less than a decade, Social Security could be out of money. But a surprising plan from Trump’s inner circle may not just save the system — it could unlock a major opportunity for savvy investors. Financial insider Jim Rickards calls it “Social Prosperity,” and says those who act now could see the biggest gains.
Psychemedics reminds stockholders to cast votes for Annual Meeting
Psychemedics Reports Improved Losses Amid Revenue Dip
See More Headlines

PMD Stock Analysis - Frequently Asked Questions

Psychemedics Co. (NASDAQ:PMD) issued its earnings results on Tuesday, November, 12th. The company reported ($0.09) earnings per share (EPS) for the quarter. The firm earned $5.20 million during the quarter. Psychemedics had a negative trailing twelve-month return on equity of 49.05% and a negative net margin of 14.59%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Psychemedics investors own include Pfizer (PFE), NVIDIA (NVDA), DraftKings (DKNG), UnitedHealth Group (UNH), Canopy Growth (CGC), Advanced Micro Devices (AMD) and McDonald's (MCD).

Company Calendar

Last Earnings
11/12/2024
Today
4/26/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Medical laboratories
Sub-Industry
Healthcare
Current Symbol
NASDAQ:PMD
Employees
140
Year Founded
1985

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-4,150,000.00
Pretax Margin
-14.55%

Debt

Sales & Book Value

Annual Sales
$22.10 million
Price / Cash Flow
N/A
Book Value
$1.15 per share
Price / Book
2.32

Miscellaneous

Free Float
5,256,000
Market Cap
$16.31 million
Optionable
Not Optionable
Beta
N/A

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:PMD) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners